Off Patent
May 2027

Rapivab

peramivir

Biocryst Pharmaceuticals Inc

Solution (intravenous) · NDA 206426

Last listed protection ends
May 7, 2027

The FDA lists 2 patents for Rapivab, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Patent 10,391,075
    Claims a use (U-2622, U-3069)
  2. Patent 8,778,997
    Claims a use (U-1627, U-2622, U-3069)